<--- Back to Details
First PageDocument Content
Heparins / Coagulation system / Angiology / Transfusion medicine / Low molecular weight heparin / P-selectin / Factor X / Angiogenesis / E-selectin / Biology / Cell biology / Selectins
Date: 2012-06-27 15:01:56
Heparins
Coagulation system
Angiology
Transfusion medicine
Low molecular weight heparin
P-selectin
Factor X
Angiogenesis
E-selectin
Biology
Cell biology
Selectins

Abstract # 5005 M-ONC 402, a novel non-anticoagulant heparin, inhibits P-Selectin function and metastatic seeding of tumor cells in mice Chia Lin Chu, Jay Duffner, Nancy Dussault, Alison Long, Sucharita Roy, Radouane Z

Add to Reading List

Source URL: www.momentapharma.com

Download Document from Source Website

File Size: 1,14 MB

Share Document on Facebook

Similar Documents

Center Information: Subcenter: Inland Northwest Blood Center Inland Northwest Blood Center 210 W. Cataldo Ave.

Center Information: Subcenter: Inland Northwest Blood Center Inland Northwest Blood Center 210 W. Cataldo Ave.

DocID: 1riKA - View Document

Microsoft Wordfile00

Microsoft Wordfile00

DocID: 1r9dZ - View Document

News Releases  Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

News Releases Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

DocID: 1qHpD - View Document

RECOTHROM, Thrombin topical (Recombinant) Package Insert

RECOTHROM, Thrombin topical (Recombinant) Package Insert

DocID: 1qv5K - View Document

Quester leads £3.1million investment in Haemostatix 23 January 2006 – Quester, a leading UK venture capital company, announced today that it has led a £3.1million investment in Haemostatix Ltd, a drug design and deve

Quester leads £3.1million investment in Haemostatix 23 January 2006 – Quester, a leading UK venture capital company, announced today that it has led a £3.1million investment in Haemostatix Ltd, a drug design and deve

DocID: 1qk7W - View Document